-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 19th, Gan & Lee Pharmaceuticals opened at 75.
44 yuan today.
As of 09:55, the stock rose 10% to 82.
08 yuan, closing the price limit
.
The stock has risen by the limit once in the past year
.
Statistics show that Gan & Lee Pharmaceutical is an important insulin manufacturer in China, and its revenue from insulin-related products accounts for more than 80% of the company's total revenue
.
In addition to Gan & Lee Pharmaceuticals, some insulin concept stocks have also followed suit in the morning trading on August 19.
For example, Tonghua Dongbao also rose 6.
1%
.
On the news, on the evening of August 18, a letter was circulated in the industry seeking opinions on the "National Organization for Insulin Concentrated Procurement Plan (Draft for Comment)"
.
The document shows that the procurement cycle for this centralized insulin procurement is 2 years, which will be calculated from the actual implementation date of the selected results
.
In terms of schedule, the opinions of relevant departments will be solicited in August 2021, the relevant work will be started in September, and the selection results will be generated according to relevant procedures
.
Implementation in early 2022
.
As a major variety of hypoglycemic drugs, the centralized procurement of insulin is already on the horizon, and with the spread of centralized procurement, the industry generally believes that the market structure will usher in great changes
.
According to data from Minet.
com, in 2020, the sales of insulin and similar drugs in public medical institutions in China will be around 27 billion yuan, a year-on-year increase of 7.
9%
.
From the perspective of market structure, Novo Nordisk, Sanofi, Eli Lilly, as well as domestic Tonghua Dongbao, Gan & Lee Pharmaceutical, United Laboratories, Wanbang Biochemical, etc.
are the main companies in the market
.
Among them, foreign-funded enterprises have relatively more advantages, occupying more than 70% of the market share
.
Guosen Securities stated in the research report that assuming the implementation of centralized insulin procurement, it will accelerate the import substitution of the insulin market and further increase the penetration rate of insulin use
.
Regarding the reasons for the stock price change of Gan & Lee Pharmaceuticals, the analysis believes that the company already has four recombinant insulins similar to long-acting insulin glargine, fast-acting insulin lispro, the company's insulin aspart and protamine zinc recombinant insulin lispro mixed injection (25R).
The product variety covers the three functional segments of insulin that are long-acting, quick-acting and intermediate-acting
.
In the future, the product line will be further enriched, and it will become a manufacturer with a full product line of recombinant insulin analogs
.
It is expected that the stock may continue to gain momentum in the market outlook
.
It is worth mentioning that if centralized insulin procurement is implemented, insulin products will also usher in a trend of price reduction
.
CITIC Construction Investment previously mentioned that if the national centralized procurement is implemented, the insulin market will indeed face pressure to reduce prices in the short term, which will have a greater impact on the market structure and business operations
.
Some investors in the pharmaceutical industry have predicted that if the national procurement of insulin is expanded to the whole country, in the face of the national market share, there may be a substantial price reduction, and the decline will exceed the previous 43% in Wuhan
.
In this context, it means that the pressure on related companies is not small
.
Taking Gan & Lee Pharmaceuticals as an example, its insulin-related products are the core products.
Once centralized procurement starts, its profits will face greater uncertainty by exchanging price for quantity
.
It is reported that Gan & Lee Pharmaceuticals will expand overseas markets to offset the risk of price reductions after insulin is included in centralized procurement
.
Previously, the company signed a licensing agreement with Sandoz under Novartis for three insulin analogs (applicable to type 1 diabetes and type 2 diabetes), and the other party can commercialize Gan & Lee's insulin products in the licensed area
.
Tonghua Dongbao, which also takes insulin products as its core products, said that it will pay close attention to the changes and progress of policies related to centralized procurement
.
At the same time, it will increase profit margins through cost reduction, efficiency increase and cost control.
It will also speed up the existing research and development pipeline, increase the variety of products on the market, offset the impact of price with the increase in sales volume, and vigorously enter the field of innovative diabetes treatment drugs.
The developed triple-target inhibitor (THDBH101 capsule/WXSHC071 capsule) has been clinically approved
.
44 yuan today.
As of 09:55, the stock rose 10% to 82.
08 yuan, closing the price limit
.
The stock has risen by the limit once in the past year
.
Statistics show that Gan & Lee Pharmaceutical is an important insulin manufacturer in China, and its revenue from insulin-related products accounts for more than 80% of the company's total revenue
.
In addition to Gan & Lee Pharmaceuticals, some insulin concept stocks have also followed suit in the morning trading on August 19.
For example, Tonghua Dongbao also rose 6.
1%
.
On the news, on the evening of August 18, a letter was circulated in the industry seeking opinions on the "National Organization for Insulin Concentrated Procurement Plan (Draft for Comment)"
.
The document shows that the procurement cycle for this centralized insulin procurement is 2 years, which will be calculated from the actual implementation date of the selected results
.
In terms of schedule, the opinions of relevant departments will be solicited in August 2021, the relevant work will be started in September, and the selection results will be generated according to relevant procedures
.
Implementation in early 2022
.
As a major variety of hypoglycemic drugs, the centralized procurement of insulin is already on the horizon, and with the spread of centralized procurement, the industry generally believes that the market structure will usher in great changes
.
According to data from Minet.
com, in 2020, the sales of insulin and similar drugs in public medical institutions in China will be around 27 billion yuan, a year-on-year increase of 7.
9%
.
From the perspective of market structure, Novo Nordisk, Sanofi, Eli Lilly, as well as domestic Tonghua Dongbao, Gan & Lee Pharmaceutical, United Laboratories, Wanbang Biochemical, etc.
are the main companies in the market
.
Among them, foreign-funded enterprises have relatively more advantages, occupying more than 70% of the market share
.
Guosen Securities stated in the research report that assuming the implementation of centralized insulin procurement, it will accelerate the import substitution of the insulin market and further increase the penetration rate of insulin use
.
Regarding the reasons for the stock price change of Gan & Lee Pharmaceuticals, the analysis believes that the company already has four recombinant insulins similar to long-acting insulin glargine, fast-acting insulin lispro, the company's insulin aspart and protamine zinc recombinant insulin lispro mixed injection (25R).
The product variety covers the three functional segments of insulin that are long-acting, quick-acting and intermediate-acting
.
In the future, the product line will be further enriched, and it will become a manufacturer with a full product line of recombinant insulin analogs
.
It is expected that the stock may continue to gain momentum in the market outlook
.
It is worth mentioning that if centralized insulin procurement is implemented, insulin products will also usher in a trend of price reduction
.
CITIC Construction Investment previously mentioned that if the national centralized procurement is implemented, the insulin market will indeed face pressure to reduce prices in the short term, which will have a greater impact on the market structure and business operations
.
Some investors in the pharmaceutical industry have predicted that if the national procurement of insulin is expanded to the whole country, in the face of the national market share, there may be a substantial price reduction, and the decline will exceed the previous 43% in Wuhan
.
In this context, it means that the pressure on related companies is not small
.
Taking Gan & Lee Pharmaceuticals as an example, its insulin-related products are the core products.
Once centralized procurement starts, its profits will face greater uncertainty by exchanging price for quantity
.
It is reported that Gan & Lee Pharmaceuticals will expand overseas markets to offset the risk of price reductions after insulin is included in centralized procurement
.
Previously, the company signed a licensing agreement with Sandoz under Novartis for three insulin analogs (applicable to type 1 diabetes and type 2 diabetes), and the other party can commercialize Gan & Lee's insulin products in the licensed area
.
Tonghua Dongbao, which also takes insulin products as its core products, said that it will pay close attention to the changes and progress of policies related to centralized procurement
.
At the same time, it will increase profit margins through cost reduction, efficiency increase and cost control.
It will also speed up the existing research and development pipeline, increase the variety of products on the market, offset the impact of price with the increase in sales volume, and vigorously enter the field of innovative diabetes treatment drugs.
The developed triple-target inhibitor (THDBH101 capsule/WXSHC071 capsule) has been clinically approved
.
